Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug BioSpaceJideytro is GSK's first approved product for lung cancer.OncologyRead full story pharminent July 23, 2026 (Last updated: July 23, 2026) BioSpace Jideytro is GSK’s first approved product for lung cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Arrowhead’s Plozasiran Cuts Triglycerides Roughly 80% in Two Phase 3 TrialsNext: Lilly plans Q1 2027 filing for obesity triple retatrutide Related Stories Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026 Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval pharminent August 6, 2026 Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026
